Chemomab Therapeutics (CMMB) Non Operating Interest Expenses (2018 - 2023)

Chemomab Therapeutics (CMMB) has reported Non Operating Interest Expenses for 4 consecutive years, with -$431000.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Non Operating Interest Expenses fell 13.42% year-over-year to -$431000.0; the trailing twelve-month figure through Dec 2023 stood at -$1.3 million (up 94.35% YoY), and the FY2023 full-year result was -$1.2 million, down 250.71% from the prior year.
• Non Operating Interest Expenses eased to -$431000.0 in Q4 2023 per CMMB's latest filing, from -$231000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $12.6 million in Q3 2019 and bottomed at -$22.9 million in Q4 2019.
• Historically, Non Operating Interest Expenses has averaged -$1.3 million across 3 years, with a median of -$237000.0 in 2022.
• The widest YoY moves for Non Operating Interest Expenses: up 17377.78% in 2019, down 10691.04% in 2019.
• Over 3 years, Non Operating Interest Expenses stood at -$22.9 million in 2019, then soared by 98.34% to -$380000.0 in 2022, then decreased by 13.42% to -$431000.0 in 2023.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$431000.0, -$231000.0, and -$259000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.